-
Insurance Barriers, Migraine Hospital Visits Linked
A review of insurance claims shows patients facing obstacles to coverage for their migraine therapies are also more likely to need emergency care for treatment.
-
Synthetic Bio Company Manufactures Research Cells
A synthetic biology company says it can now produce engineered cells from stem cells for research to precise specifications, and in large quantities and consistent quality.
-
Crop Health Device Company Raises $3.5M in Early Funds
A company detecting early-stage crop diseases with handheld devices and artificial intelligence is raising $3.5 million in its seed venture round.
-
Neuro Biomarkers, Home EEG Assessed in Upcoming Trial
A digital biomarkers company and developer of neuroscience analytics are collaborating on a study of EEG measurements and algorithms with a wearable device at home.
-
Companies Partner on A.I., Fusion Energy for Space Flight
A developer of fusion energy for space travel and software company for space flight systems are writing machine learning algorithms to design a hyper-fast rocket engine.
-
Infographic – Top A.I. Work Impact Expected in Financial Services
Generative artificial intelligence is expected to affect more work processes in banking and insurance than other industries, according to a recent study.
-
Device Company, Medical Center Partner on Blood Infections Trial
A developer of detection systems for infections and university medical center plan a clinical trial to evaluate a sepsis device for helping patients with blood stream infections.
-
Partnership to Mass-Produce Graphene Biosensors
A biological testing device company and industrial graphene manufacturer are collaborating on large-scale production of graphene biosensors for widespread use.
-
Targeted Genetic Nanoparticle Company Gains $25M in Seed Funds
A developer of nanoscale lipid particles for delivering genomic therapies to specific cells and tissue, spun-off from academic labs, is raising $25 million in seed funds.
-
Vaccine Patch Shown Safe, Induces Immune Response
Initial results from a clinical trial show a patch device delivering a Covid-19 vaccine is well tolerated by recipients and triggers a measurable immune response.